CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.

In our earlier research, utilizing a B cell vaccine (scFv-Her2), the concentrating on of tumor-associated antigen Her2 (human epidermal progress issue receptor-2) to B cells by way of the anti-CD19 single chain variable fragment (scFv) was proven to enhance tumor-specific immunity, which enhanced tumor management in the prophylactic and therapeutic setting. However, the fusion protein … Read more